SCI Pharmtech Inc is a Taiwan-based company mainly engaged in the research, development, manufacturing, and sales of active pharmaceutical ingredients (APIs), API intermediates, and specialty and precision chemicals. The Company's main product categories are APIs, API intermediates, and specialty chemicals. The Company primarily sells its products in Europe, Asia, the Americas, and other domestic and international markets.

Employees

239

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-13	NT$44.60	-1.98%	137,337
26-07-13	NT$45.50	0.00%	114,013
26-07-09	NT$45.50	+1.68%	139,438
26-07-08	NT$44.75	0.00%	75,397
26-07-07	NT$44.75	-1.32%	128,155

End-of-day quote Taiwan S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Taiwan S.E. Other stock markets 2026-07-14			5-day change	1st Jan Change
44.60 ^TWD	-1.98%		-1.65%	-8.42%

05-07	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	5.33B 166M 145M 135M 124M 234M 15.85B 239M 1.6B 629M 7.79B 622M 608M 26.89B	P/E 2024	20.3x	P/E 2025	54.2x
Enterprise Value	6.24B 194M 170M 158M 145M 274M 18.57B 280M 1.88B 737M 9.12B 728M 713M 31.49B	EV / Sales 2024	7.3x	EV / Sales 2025	5.01x
Free-Float	55.34%	Yield 2024	1.66%	Yield 2025	1.54%

05-07	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-05	SCI Pharmtech, Inc. Proposes Dividend Distribution for the Period from January 1, 2025 to December 31, 2025	CI
11-07	SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-06	SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-05	SCI Pharmtech, Inc. Announces Cash Dividend, Payable on August 5, 2025	CI
25-05-26	SCI Pharmtech, Inc. Announces Changes to its Board, Effective May 26, 2025	CI
25-05-08	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-10	Sci Pharmtech, Inc. Declares Dividend for Period from January 01, 2024 to December 31, 2024	CI
25-03-09	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-09	Sci Pharmtech, Inc. Announces Cash Dividend Payment	CI
24-12-20	Sci Pharmtech, Inc. Announces Appointment of Members of the Sustainable Development Committee	CI
24-11-08	SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

22-06-29	SCI Pharmtech : Notice of appointment of general manager of the Board of Directors.	PU
22-06-29	SCI Pharmtech : Notice of the re-election of chairman of the Board of Directors.	PU
22-06-21	SCI Pharmtech : List of the Company's elected directors.	PU
22-06-21	SCI Pharmtech : Notice of the resolutions of 2022 general shareholders' meeting.	PU
22-06-21	SCI Pharmtech : Notice of re-election of functional committees' members	PU

SCI Pharmtech, Inc. Stock

Stocks

4119

TW0004119003

Pharmaceuticals

Valuation: SCI Pharmtech, Inc.

Chart: SCI Pharmtech, Inc.

Latest news : SCI Pharmtech, Inc.

Press Releases: SCI Pharmtech, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: SCI Pharmtech, Inc.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	-1.98%
1 week	-1.65%
Current month	-0.45%
1 month	+7.21%
3 months	-12.20%
6 months	-13.57%
Current year	-8.42%

1 week	44.1	46.5
1 month	41.05	46.5
Current year	39.6	55.5
1 year	39.6	63.7
3 years	39.6	106.5
5 years	39.6	119.56
10 years	39.6	119.56

Manager	Title	Age	Since
Wei Chun Weng CEO	Chief Executive Officer	-	-
Wen Chen Yang DFI	Director of Finance/CFO	-	2002-12-31
Wen Chih Chou PRN	Corporate Officer/Principal	-	2010-08-31

Director	Title	Age	Since
Hsiang Li Chen BRD	Director/Board Member	-	2001-12-16
Wei Chun Weng CHM	Chairman	-	2001-12-16
Wen Chih Chou BRD	Director/Board Member	-	2010-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCI PHARMTECH, INC.	-1.98%	-1.65%	-28.30%	-52.89%	169M
MERCK & CO., INC.	-2.72%	-6.06%	+44.68%	+12.77%	306B
MERCK KGAA	-0.25%	-1.59%	+26.99%	-6.69%	69.32B
HALOZYME THERAPEUTICS, INC.	-0.91%	-7.38%	+31.05%	+97.67%	9.03B
KYOWA KIRIN CO., LTD.	+1.16%	-2.74%	+7.28%	+2.31%	8.48B
SK BIOPHARMACEUTICALS CO., LTD.	-5.93%	-11.19%	-24.11%	-1.45%	4.16B
BETTA PHARMACEUTICALS CO., LTD.	+8.22%	+1.63%	+20.93%	+34.83%	4B
YUHAN CORPORATION	-2.06%	-4.17%	-40.29%	+18.10%	3.4B
SUPERNUS PHARMACEUTICALS, INC.	-0.67%	-1.86%	+38.55%	+56.68%	2.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.57%	-1.94%	+12.52%	-19.39%	2.15B
Average	-0.36%	-1.02%	+8.93%	+14.19%	40.98B
Weighted average by Cap.	-2.08%	-3.97%	+38.73%	+11.35%

	2024	2025
Net sales	1.52B 47.35M 41.53M 38.47M 35.39M 66.95M 4.53B 68.25M 458M 180M 2.23B 178M 174M 7.69B	1.34B 41.76M 36.63M 33.92M 31.21M 59.04M 4B 60.19M 404M 159M 1.96B 157M 153M 6.78B
Net income	535M 16.62M 14.57M 13.5M 12.42M 23.49M 1.59B 23.95M 161M 63.1M 781M 62.4M 61.03M 2.7B	107M 3.34M 2.93M 2.71M 2.49M 4.72M 319M 4.81M 32.31M 12.67M 157M 12.53M 12.26M 542M
Net Debt	298M 9.25M 8.11M 7.51M 6.91M 13.08M 885M 13.33M 89.56M 35.12M 435M 34.73M 33.97M 1.5B	912M 28.35M 24.87M 23.03M 21.19M 40.09M 2.71B 40.87M 275M 108M 1.33B 106M 104M 4.6B